Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH1188-11 in advanced NSCLC
NCT03231475Phase 1Withdrawn
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jul 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SPH1188-11 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Planned start Jul 2017; status: withdrawn.
02
Drugs
SPH1188-11
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03231475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231475.